Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2008 Apr;83(4):619-21. Epub 2007 Dec 19.

    Monoamine oxidase inhibition for tobacco pharmacotherapy.

    Source

    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. tony.george@utoronto.ca

    Abstract

    Tobacco addiction is the most significant preventable cause of morbidity and mortality in the Western world, with >430,000 deaths annually from tobacco-related diseases being reported in the United States. Although effective treatments are available for cessation of smoking (e.g., nicotine replacement therapies, sustained-release bupropion and varenicline), they do not work for all smokers. Therefore the development of more effective medications for treating tobacco dependence, based on novel mechanisms, is a high priority. This article reviews the links between smoking and monoamine oxidase (MAO) inhibition, which could lead to the development of novel pharmacotherapies to treat tobacco dependence.

    PMID:
    18091758
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk